Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Astellas Pharma ( (JP:4503) ) has shared an update.
Astellas Pharma has received conditional approval from the Japanese Ministry of Health, Labor and Welfare for IZERVAY, making it the first approved treatment for suppressing geographic atrophy growth in age-related macular degeneration in Japan. This approval, achieved through an expedited pathway, is expected to significantly impact the treatment landscape for the estimated 100,000 people in Japan affected by this condition, potentially reducing the progression of visual impairment and enhancing patient access to innovative therapies.
The most recent analyst rating on (JP:4503) stock is a Hold with a Yen1900.00 price target. To see the full list of analyst forecasts on Astellas Pharma stock, see the JP:4503 Stock Forecast page.
More about Astellas Pharma
Astellas is a global life sciences company focused on providing transformative therapies in areas such as oncology, ophthalmology, urology, immunology, and women’s health. They are dedicated to pioneering healthcare solutions for diseases with high unmet medical needs through their research and development programs.
Average Trading Volume: 6,674,891
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen2980.3B
Find detailed analytics on 4503 stock on TipRanks’ Stock Analysis page.